SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19...
One vaccine, MVA-SARS-2-S, expressed the native form of the S protein [19], whereas the second vaccine, MVA-SARS-2-ST, expressed a modified prefusion stabilized form of the S protein [20]. Both vaccines were highly immunogenic when tested in a preclinical mouse model, inducing strong ...
Keywords: MVA-T7pol;SARS-CoV-2;immunoassay;pandemic preparedness;membrane protein;ORF3a protein;visualization;rapid detection